WuXi PharmaTech signed a second agreement with Open Monoclonal Technology, a California company that produces transgenic animals for development of human therapeutic antibodies. Under the new agreement, WuXi’s clients using OMT's OmniRat™ and OmniMouse™ technologies will have the option of developing their products either for global markets or regionally in China, Japan, Korea or other Asian territories. If a client secures rights only in Asia (or some part of Asia), the global rights will remain with OMT. More details.... Stock Symbol: (NYSE: WX) Share this with colleagues: // //